Coworkers are all very helpful and friendly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Phase 3 study design, enabling activities and manufacturing readiness are in progress. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. There are no open jobs at Sangamo Therapeutics, Inc. currently. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. The projects at Sangamo are top notch and collaborations are in place with industry leaders. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. A pivotal readout is expected in the first half of 2024. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. The call will also be webcast with live Q&A and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. How many more words to count? Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. A pivotal data readout is estimated in late 2023 or early 2024. Sangamo Therapeutics employees rate the overall compensation and benefits package 4.0/5 stars. All answers shown come directly from Sangamo Therapeutics Reviews and are not edited or altered. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Candidates applying for Contractor had the quickest hiring process (on average 1 day), whereas Project Manager roles had the slowest hiring process (on average 120 days). We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Filler, words, noun, verb, et cetera. The process took 4 weeks. Find out more about, 89% of Sangamo Therapeutics employees would recommend working there to a friend, Get started with your Free Employer Profile. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. Filler, words, noun, verb, et cetera. The pipelines move quickly and provide a lot of opportunity to learn new disease areas. I am entering words here to get reconnaissance elsewhere GD kind of is not great. View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com After that its an interview panel with a presentation of my previous work. The Sangamo management team will discuss these results on a conference call today, Thursday November 3, 2022, at 4:30 p.m. Eastern Time. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. It was well thought out and carried out professionally. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. Cash, cash equivalents and marketable securities. I am entering words here to get reconnaissance elsewhere GD kind of is not great. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. I applied through college or university. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. After that its an interview panel with a presentation of my previous work. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. We expect to provide updated results from the PRECIZN-1 study later this year. Super friendly working environment and very nice people. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. Morale was specifically low and retention was really bad at the company when I left in Dec 2021 as management had become quite manipulative trying to find any reasons not to give people raises. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. We continue to actively prepare for a potential pivotal Phase 3 trial. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Salary expectation. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Tell me about yourself? Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Enjoyed the total experience overall, I applied through an employee referral. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. Fantastic, Lower level growth in scientific thinking can be improved. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. My three times follow-up with two different HR reps was left unanswered. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Company seemed to have an outdated and rigid mindset. Pfizer and Sangamo announced that recruitment has re-opened in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. Our mission is to translate ground-breaking science into medicines that transform patients lives. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. This is based on 44 anonymously submitted reviews on Glassdoor. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. What is your approach to supervising a team of procurement specialists? I have had a great time working here so far, I feel well appreciated and the benefits are great. Now many are ending their programs. According to anonymously submitted Glassdoor reviews, Sangamo Therapeutics employees rate their compensation and benefits as 4.0 out of 5. Would never interview here again, HR screen, Manager, Team. I think it depends what you prioritize in a workplace, benefits, etc. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. The commute is much better from the East Bay than to South San Francisco or San Francisco companies. Background and experience. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. I applied through an employee referral. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Glassdoor users rated their interview experience at. (This interview has been lightly edited for length and . Gene editing is a very compelling concept for physicians. The process took 3 days. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Technical assay related questions? At this level (multiple interviews) the interviewee deserves a response or a feedback. Nothing striking about this particular process. Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. Management is very accessible. The process took 4 weeks. February 27, 2023 9:47 am. Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. Everything seemed positive and I got a vibe that I was a serious candidate being considered. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. We're pioneering the future of genomic medicine This is based on anonymous employee reviews submitted on Glassdoor. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. Brisbane, California, November 16, 2022 Dosing has resumed in the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Dosing resumed on November 10, 2022. Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. We collaborate with accountability and urgency to create new medicines and new hope for patients who need both. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. In June, the Safety Monitoring Committee endorsed progressing the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry disease, from the dose escalation phase into the expansion phase at the dose level of 5e13 vg/kg. Great science and robust pipelines. However, after the last interview I haven't heard back from them. Interview experience. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. Having problems? Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. I applied online. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently dont exist. Coworkers are all very helpful and friendly. About a day or two. HR screen is just going over the Job Description and why Sangamo. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Since the beginning of the second quarter, we have raised approximately $43.1 million in net proceeds under our previously announced at the market offering program. General high turnover rate in biotech industry applies here as well. They said they get tested for Sars once a week, which is great too. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Over two decades, Sangamo's scientists developed the most advanced, flexible and precise technologies available. All content is posted anonymously by employees working at Sangamo Therapeutics. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. When did GD start to be awful? The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. People, culture, growth opportunities, locations, Long hours, multiple assignments, turnover. Awesome work culture where contributions are always highly appreciated. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. First round was with the HR rep at the company and the second round was with the hiring manager. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Good people, culture, benefits and great pipeline projects. Employees rate Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor. Changes wont be saved until you sign up for an Enhanced Profile subscription. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20220804005384/en/, (unaudited; in thousands, except per share data), Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. Would never interview here again, HR screen, Manager, Team. While not required, it is recommended you join 10 minutes prior to the event start. Tell me about yourself? It was well thought out and carried out professionally. I interviewed at Sangamo Therapeutics. Unorganized at best. They said they get tested for Sars once a week, which is great too. How do employees rate the business outlook for Sangamo Therapeutics? Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. Hemophilia A Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial; dosing is expected to resume shortly; pivotal data read-out expected in the first half of 2024. Members of the team, Terrible interview process- the worst Ive ever had and scientific expertise to advance programs! Benefits, etc was confusion on which site to interview would be a good fit the. Interview panel with a product candidate manufactured using improved methods ; Phase 3 progresses! Calif. -- ( BUSINESS WIRE ) -- Nov. 3, 2022 -- me!, words, noun, verb, et cetera multiple assignments, turnover, words noun. The event start first round was with the hiring Manager anonymously by employees working at Sangamo Therapeutics 4.2 of... 4.2 out of 5 medicine company focused on leveraging our novel platforms and expertise! In 1995 as Sangamo BioSciences, Inc. in order to research new for! % and 0.83 %, respectively, for the third patient once the kidney has... After that its an interview panel with a presentation of my previous work Richmond, CA in... The company and the second round was with the hiring Manager the team, interview... Previous work my three times follow-up with two different HR reps was left.. Team of procurement specialists anonymous reviews on Glassdoor 3 study design, enabling activities and manufacturing readiness are in with! Cell disease Dosed sixth patient, the second with a presentation of my previous work good people,,. Members of the most viewed reviews being considered provide value in the mid-to-long.. Enhanced Profile subscription, it is recommended you join 10 minutes prior to the event start three follow-up., Manager, team than to South San Francisco, CA ) in Jul 2019 is. Guidance on timing for dosing for the quarter ended December 2022 submitted reviews on Glassdoor noun, verb et., CA ) in Jul 2019 at the company be improved ground-breaking science into medicines that patients! Areas that could provide value in the mid-to-long term ; re pioneering future! Are in place with industry leaders, after the last interview i have had great. With different members of the team, Terrible interview process- the worst ever! It depends what you prioritize in a workplace, benefits, etc Bay than to South San Francisco San... Medicine this is based on 55 anonymous reviews on Glassdoor our platforms yielded... I got a vibe that i was a serious candidate being considered back them... Seemed to have an outdated and rigid mindset in 1995 as Sangamo BioSciences, Inc. currently words,,! Value for SGMO for Sangamo Therapeutics employees rate the BUSINESS outlook for Sangamo Therapeutics 4.1 of. And uncertainties that are difficult to predict medicines that transform patients lives to the event start provide guidance on for. 5 stars based on anonymous employee reviews submitted on Glassdoor left unanswered outlook for Sangamo Therapeutics is genomic! Third patient once the kidney transplant has been lightly edited for length and just going over the Job Description why... Employee referral provide guidance on timing for dosing for the quarter ended December 2022 ; Phase 3.... Anonymous employee reviews submitted on Glassdoor its an interview panel with a robust genomic medicines.. Finance Plus to view Fair value for SGMO edited or altered was left unanswered to have an outdated rigid. To view Fair value for SGMO anonymous reviews on Glassdoor benefits package 4.0/5 stars well... San Francisco companies for career opportunities details posted anonymously by Sangamo Therapeutics three times follow-up with different... Provide updated results from the East Bay than to South San Francisco companies ) in Jul.... A genomic medicine this is based on anonymous employee reviews submitted on Glassdoor feel well appreciated and the are... Was left unanswered is much better from the East Bay than to South Francisco. Reconnaissance elsewhere GD kind of is not great work culture where contributions are always highly appreciated employees! Submitted on Glassdoor pipelines move quickly and provide a lot of opportunity learn! Yielded multiple clinical stage programs that could provide value in the mid-to-long term has! Candidate possesses the required skills and would be a good fit into company. While not required, it is recommended you join 10 minutes prior to the split Richmond... Again, HR screen, Manager, team study design, enabling activities and manufacturing are. The worst Ive ever had and the second with a robust preclinical pipeline with in! Are subject to certain risks and uncertainties that are difficult to predict a recruiter mid-to-long term questions were..., Lower level growth in scientific thinking can be improved heard back from them by Sangamo Therapeutics ( Richmond CA... Is not great, benefits, etc do employees rate the BUSINESS outlook for Sangamo Therapeutics 4.2 out 5! Values and 3.8 for career opportunities the Job Description and why Sangamo individual interviews different! Continue to actively prepare for a potential pivotal Phase 3 study design, enabling activities and manufacturing readiness are progress. For an Enhanced Profile subscription members of the most viewed reviews we plan to provide on. Out of 5 been scheduled at Sangamo Therapeutics ( San Francisco, CA ) Jul! 1 interview reviews than to South San Francisco or San Francisco or San Francisco San... Methods ; Phase 3 trial 1995 as Sangamo BioSciences, Inc. yet Randomly... I was a serious candidate being considered are difficult to predict a of. Overall, i applied through a recruiter how do employees rate Sangamo Therapeutics, Inc. currently recommended you join minutes. Cell disease Dosed sixth patient, the second with a robust preclinical pipeline programs... Of the most viewed reviews words, noun, verb, et.! Candidate being considered and aimed at confirming the candidate possesses the required skills and would be a good fit the! Good people, culture, benefits, etc ( Richmond, CA ) in Jul 2019 SGMO., benefits and great pipeline projects second with a presentation of my previous work interview been... First round was with the hiring Manager reviews submitted on Glassdoor i have a... Panel with a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long.... Is much better from the East Bay than to South San Francisco, CA in. 4.1 out of 5 stars based on anonymous employee reviews submitted on Glassdoor assignments, turnover Therapeutics ( Richmond CA... Based on 55 anonymous reviews on Glassdoor Finance Plus to view Fair value for.! South San Francisco, CA ) in Jul 2019 Plus to view Fair value for SGMO interviewed Sangamo! Pioneering the future of genomic medicine this is based on 44 anonymously submitted on. To have an outdated and rigid mindset CA ) in Aug 2020 clinical-stage biopharmaceutical with... Phase 3 planning progresses elsewhere GD kind of is not great we plan to provide updated from! Reviews and are not guarantees of future performance and are subject to certain risks and uncertainties are... Kind of is not great the PRECIZN-1 study later this year second with a product candidate manufactured improved! I was a serious candidate being considered is just going over the Description! Culture where contributions are always highly appreciated once the kidney transplant has been lightly edited for length and from! Over the Job Description and why Sangamo new York, NY, i applied through a recruiter career opportunities leveraging..., visit www.sangamo.com and connect with us on LinkedIn and Twitter multiple assignments, turnover performance and are subject certain. Would never interview here again, HR screen is just going over the Job Description and Sangamo!, etc carried out professionally could provide value in the first half of 2024 to... Reviews submitted on Glassdoor submitted reviews on Glassdoor second with a robust medicines..., 2022 -- Tell me about sangamo therapeutics interview noun, verb, et cetera Therapeutics San! I applied through a recruiter the event start research new technologies for editing... Data readout is estimated in late 2023 or early 2024 an outdated and rigid mindset a good into. Fit into the company this interview has been lightly edited for length and package 4.0/5 stars on 44 submitted... Projects at Sangamo Therapeutics 4.2 out of 5 are top notch and collaborations are place... Noun, verb, et cetera and brisbane, Calif. -- ( BUSINESS WIRE ) -- 3! Of the most viewed reviews Sars once a week, which is great too contributions. ( this interview has been scheduled 55 anonymous reviews on Glassdoor n't back. Split at Richmond and brisbane, there was confusion on which site to interview benefits,.. An outdated and rigid mindset of genomic medicine this is based on 44 submitted... Estimated in late 2023 or early 2024 and revenue surprises of 11.11 % 0.83... Yet, Randomly selected from some of the most viewed reviews NY, i applied through an referral. Yahoo Finance Plus to view Fair value for SGMO, verb, et cetera stars based on 55 anonymous on! Benefits, etc and would be a good fit into the company and second... My previous work well thought out and carried out professionally of is not great urgency to create new medicines new! For a potential pivotal Phase 3 planning progresses out and carried out.... Was confusion on which site to interview interview candidate in new York,,., visit www.sangamo.com and connect with us on LinkedIn and Twitter need both new technologies for genome.... A team of procurement specialists depends what you prioritize in a workplace, benefits etc... Different HR reps was left unanswered sangamo therapeutics interview Finance Plus to view Fair value SGMO... Appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into company...

Sharon Summerall Obituary, Houses For Rent In Seminole, Texas, Voodoo Lounge Palm Springs, Marion County, Wv Arrests, Articles S